Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)

BACKGROUND: ABP501 is a biosimilar to Reference Adalimumab (HUMIRA®) produced by AMGEN. Adalimumab (ADA) has a marketing authorization for Crohn's disease, ulcerative colitis and other inflammatory or autoimmune diseases. The aim of this study was to evaluate the LISA-TRACKER assays developed b...

Descripción completa

Detalles Bibliográficos
Autores principales: Francois, Fabien, Naimi, Loubna, Roblin, Xavier, Berger, Anne-Emmanuelle, Paul, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710016/
https://www.ncbi.nlm.nih.gov/pubmed/34953484
http://dx.doi.org/10.1186/s12865-021-00473-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710016/
https://www.ncbi.nlm.nih.gov/pubmed/34953484
http://dx.doi.org/10.1186/s12865-021-00473-1

Ejemplares similares